Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative
June 21, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References Re33107 Process for alleviating proliferative skin diseases Topical use of dyphylline and dyphylline containing compositions Process for treating proliferative skin diseases using certain 6,8-substituted ribofuranosylpurine-3',5'-cyclic phosphates Process for the synthesis of 1,23(S),25-trihydroxycholecalciferol and 1,23(R),25-trihydroxycholecalciferol 25,26-Dehydro-1,23(S,R)-dihydroxycholecalciferol and its epimers Calcium phosphate type crystallizable glass 1,25-dihydroxy-26,27-dimethylcholecalciferol and its use in the treatment of calcium pathobolism Histamine H1 antagonists Side-chain unsaturated 1-hydroxyvitamin D compounds InventorsAssigneeApplicationNo. 263399 filed on 06/21/1994US Classes:514/263.34Chalcogen bonded directly to the 2-and 6- positions of the purine ring system (e.g., theophylline, etc.)ExaminersPrimary: Prior, Kimberly J.Attorney, Agent or FirmForeign Patent References
International ClassA61K 031/52Foreign Application Priority Data1991-09-02 ILAbstractUse of a compound selected from the group consisting of pentoxifylline, propentofylline and torbafylline for topical treatment of psoriasis or atopic dermatitis and pharmaceutical compositions comprising them.Other References
| |
